Richard G. Kibbey
Yale University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Richard G. Kibbey.
Nature | 2014
Anila K. Madiraju; Derek M. Erion; Yasmeen Rahimi; Xian-Man Zhang; Demetrios T. Braddock; Ronald A. Albright; Brett J. Prigaro; John L. Wood; Sanjay Bhanot; Michael J. MacDonald; Michael J. Jurczak; João-Paulo G. Camporez; Hui-Young Lee; Gary W. Cline; Varman T. Samuel; Richard G. Kibbey; Gerald I. Shulman
Metformin is considered to be one of the most effective therapeutics for treating type 2 diabetes because it specifically reduces hepatic gluconeogenesis without increasing insulin secretion, inducing weight gain or posing a risk of hypoglycaemia. For over half a century, this agent has been prescribed to patients with type 2 diabetes worldwide, yet the underlying mechanism by which metformin inhibits hepatic gluconeogenesis remains unknown. Here we show that metformin non-competitively inhibits the redox shuttle enzyme mitochondrial glycerophosphate dehydrogenase, resulting in an altered hepatocellular redox state, reduced conversion of lactate and glycerol to glucose, and decreased hepatic gluconeogenesis. Acute and chronic low-dose metformin treatment effectively reduced endogenous glucose production, while increasing cytosolic redox and decreasing mitochondrial redox states. Antisense oligonucleotide knockdown of hepatic mitochondrial glycerophosphate dehydrogenase in rats resulted in a phenotype akin to chronic metformin treatment, and abrogated metformin-mediated increases in cytosolic redox state, decreases in plasma glucose concentrations, and inhibition of endogenous glucose production. These findings were replicated in whole-body mitochondrial glycerophosphate dehydrogenase knockout mice. These results have significant implications for understanding the mechanism of metformin’s blood glucose lowering effects and provide a new therapeutic target for type 2 diabetes.
Nature | 2016
Rachel J. Perry; Liang Peng; Natasha A. Barry; Gary W. Cline; Dongyan Zhang; Rebecca L. Cardone; Kitt Falk Petersen; Richard G. Kibbey; Andrew L. Goodman; Gerald I. Shulman
Obesity, insulin resistance and the metabolic syndrome are associated with changes to the gut microbiota; however, the mechanism by which modifications to the gut microbiota might lead to these conditions is unknown. Here we show that increased production of acetate by an altered gut microbiota leads to activation of the parasympathetic nervous system which in turn promotes increased glucose-stimulated insulin secretion (GSIS), increased ghrelin secretion, hyperphagia, obesity and its related sequelae (Extended Data Fig. 1). Taken together, these data identify increased acetate production by a nutrient-gut microbiota interaction and subsequent parasympathetic activation as possible therapeutic targets for obesity.
Proceedings of the National Academy of Sciences of the United States of America | 2007
Dongyan Zhang; Zhen-Xiang Liu; Cheol Soo Choi; Liqun Tian; Richard G. Kibbey; Jianying Dong; Gary W. Cline; Philip A. Wood; Gerald I. Shulman
Alterations in mitochondrial function have been implicated in the pathogenesis of insulin resistance and type 2 diabetes. However, it is unclear whether the reduced mitochondrial function is a primary or acquired defect in this process. To determine whether primary defects in mitochondrial β-oxidation can cause insulin resistance, we studied mice with a deficiency of long-chain acyl-CoA dehydrogenase (LCAD), a key enzyme in mitochondrial fatty acid oxidation. Here, we show that LCAD knockout mice develop hepatic steatosis, which is associated with hepatic insulin resistance, as reflected by reduced insulin suppression of hepatic glucose production during a hyperinsulinemic-euglycemic clamp. The defects in insulin action were associated with an ≈40% reduction in insulin-stimulated insulin receptor substrate-2-associated phosphatidylinositol 3-kinase activity and an ≈50% decrease in Akt2 activation. These changes were associated with increased PKCε activity and an aberrant 4-fold increase in diacylglycerol content after insulin stimulation. The increase in diacylglycerol concentration was found to be caused by de novo synthesis of diacylglycerol from medium-chain acyl-CoA after insulin stimulation. These data demonstrate that primary defects in mitochondrial fatty acid oxidation capacity can lead to diacylglycerol accumulation, PKCε activation, and hepatic insulin resistance.
Cell | 2013
William J. Israelsen; Talya L. Dayton; Shawn M. Davidson; Brian Prescott Fiske; Aaron M. Hosios; Gary Bellinger; Jie Li; Yimin Yu; Mika Sasaki; James W. Horner; Laura N. Burga; Jianxin Xie; Michael J. Jurczak; Ronald A. DePinho; Clary B. Clish; Tyler Jacks; Richard G. Kibbey; Gerburg Wulf; Dolores Di Vizio; Gordon B. Mills; Lewis C. Cantley; Matthew G. Vander Heiden
The pyruvate kinase M2 isoform (PKM2) is expressed in cancer and plays a role in regulating anabolic metabolism. To determine whether PKM2 is required for tumor formation or growth, we generated mice with a conditional allele that abolishes PKM2 expression without disrupting PKM1 expression. PKM2 deletion accelerated mammary tumor formation in a Brca1-loss-driven model of breast cancer. PKM2 null tumors displayed heterogeneous PKM1 expression, with PKM1 found in nonproliferating tumor cells and no detectable pyruvate kinase expression in proliferating cells. This suggests that PKM2 is not necessary for tumor cell proliferation and implies that the inactive state of PKM2 is associated with the proliferating cell population within tumors, whereas nonproliferating tumor cells require active pyruvate kinase. Consistent with these findings, variable PKM2 expression and heterozygous PKM2 mutations are found in human tumors. These data suggest that regulation of PKM2 activity supports the different metabolic requirements of proliferating and nonproliferating tumor cells.
Current Opinion in Biotechnology | 2015
Joerg Martin Buescher; Maciek R. Antoniewicz; Laszlo G. Boros; Shawn C. Burgess; Henri Brunengraber; Clary B. Clish; Ralph J. DeBerardinis; Olivier Feron; Christian Frezza; Bart Ghesquière; Eyal Gottlieb; Karsten Hiller; Russell G. Jones; Jurre J. Kamphorst; Richard G. Kibbey; Alec C. Kimmelman; Jason W. Locasale; Sophia Y. Lunt; Oliver Dk Maddocks; Craig R. Malloy; Christian M. Metallo; Emmanuelle J. Meuillet; Joshua Munger; Katharina Nöh; Joshua D. Rabinowitz; Markus Ralser; Uwe Sauer; Gregory Stephanopoulos; Julie St-Pierre; Daniel A. Tennant
Measuring intracellular metabolism has increasingly led to important insights in biomedical research. (13)C tracer analysis, although less information-rich than quantitative (13)C flux analysis that requires computational data integration, has been established as a time-efficient method to unravel relative pathway activities, qualitative changes in pathway contributions, and nutrient contributions. Here, we review selected key issues in interpreting (13)C metabolite labeling patterns, with the goal of drawing accurate conclusions from steady state and dynamic stable isotopic tracer experiments.
Diabetes | 2011
Michael J. Jurczak; Hui-Young Lee; Andreas L. Birkenfeld; François R. Jornayvaz; David W. Frederick; Rebecca L. Pongratz; Xiaoxian Zhao; Gilbert W. Moeckel; Varman T. Samuel; Jean M. Whaley; Gerald I. Shulman; Richard G. Kibbey
OBJECTIVE Inhibition of the Na+-glucose cotransporter type 2 (SGLT2) is currently being pursued as an insulin-independent treatment for diabetes; however, the behavioral and metabolic consequences of SGLT2 deletion are unknown. Here, we used a SGLT2 knockout mouse to investigate the effect of increased renal glucose excretion on glucose homeostasis, insulin sensitivity, and pancreatic β-cell function. RESEARCH DESIGN AND METHODS SGLT2 knockout mice were fed regular chow or a high-fat diet (HFD) for 4 weeks, or backcrossed onto the db/db background. The analysis used metabolic cages, glucose tolerance tests, euglycemic and hyperglycemic clamps, as well as isolated islet and perifusion studies. RESULTS SGLT2 deletion resulted in a threefold increase in urine output and a 500-fold increase in glucosuria, as well as compensatory increases in feeding, drinking, and activity. SGLT2 knockout mice were protected from HFD-induced hyperglycemia and glucose intolerance and had reduced plasma insulin concentrations compared with controls. On the db/db background, SGLT2 deletion prevented fasting hyperglycemia, and plasma insulin levels were also dramatically improved. Strikingly, prevention of hyperglycemia by SGLT2 knockout in db/db mice preserved pancreatic β-cell function in vivo, which was associated with a 60% increase in β-cell mass and reduced incidence of β-cell death. CONCLUSIONS Prevention of renal glucose reabsorption by SGLT2 deletion reduced HFD- and obesity-associated hyperglycemia, improved glucose intolerance, and increased glucose-stimulated insulin secretion in vivo. Taken together, these data support SGLT2 inhibition as a viable insulin-independent treatment of type 2 diabetes.
Cell Metabolism | 2008
Over Cabrera; M. Caroline Jacques-Silva; Stephan Speier; Shao Nian Yang; Martin Köhler; Alberto Fachado; Elaine Vieira; Juleen R. Zierath; Richard G. Kibbey; Dora M. Berman; Norma S. Kenyon; Camillo Ricordi; Alejandro Caicedo; Per-Olof Berggren
An important feature of glucose homeostasis is the effective release of glucagon from the pancreatic alpha cell. The molecular mechanisms regulating glucagon secretion are still poorly understood. We now demonstrate that human alpha cells express ionotropic glutamate receptors (iGluRs) that are essential for glucagon release. A lowering in glucose concentration results in the release of glutamate from the alpha cell. Glutamate then acts on iGluRs of the AMPA/kainate type, resulting in membrane depolarization, opening of voltage-gated Ca(2+) channels, increase in cytoplasmic free Ca(2+) concentration, and enhanced glucagon release. In vivo blockade of iGluRs reduces glucagon secretion and exacerbates insulin-induced hypoglycemia in mice. Hence, the glutamate autocrine feedback loop endows the alpha cell with the ability to effectively potentiate its own secretory activity. This is a prerequisite to guarantee adequate glucagon release despite relatively modest changes in blood glucose concentration under physiological conditions.
Journal of Biological Chemistry | 2007
Rebecca L. Pongratz; Richard G. Kibbey; Gerald I. Shulman; Gary W. Cline
In islet β-cells and INS-1 cells both the high activity of malic enzyme and the correlation of insulin secretion rates with pyruvate carboxylase (PC) flux suggest that a pyruvate-malate cycle is functionally relevant to insulin secretion. Expression of the malic enzyme isoforms in INS-1 cells and rat islets was measured, and small interfering RNA was used to selectively reduce isoform mRNA expression in INS-1 cells to evaluate its impact on insulin secretion. The cytosolic NADP+-specific isoform (ME1) was the most abundant, with the mitochondrial isoforms NAD+-preferred (ME2) expressed at ∼50%, and the NADP+-specific (ME3) at ∼10% compared with ME1. Selective reduction (89 ± 2%) of cytosolic ME1 mRNA expression and enzyme activity significantly reduced glucose (15 mm:41 ± 6%, p < 0.01) and amino acid (4 mm glutamine ± 10 mm leucine: 39 ± 6%, p < 0.01)-stimulated insulin secretion. Selective small interfering RNA reduction (51 ± 6%) of mitochondrial ME2 mRNA expression did not impact glucose-induced insulin secretion, but decreased amino acid-stimulated insulin secretion by 25 ± 4% (p < 0.01). Modeling of the metabolism of [U-13C]glucose by its isotopic distribution in glutamate indicates a second pool of pyruvate distinct from glycolytically derived pyruvate in INS-1 cells. ME1 knockdown decreased flux of both pools of pyruvate through PC. In contrast, ME2 knockdown affected only PC flux of the pyruvate derived from glutamate metabolism. These results suggest a physiological basis for two metabolically and functionally distinct pyruvate cycles. The cycling of pyruvate by ME1 generates cytosolic NADPH, whereas mitochondrial ME2 responds to elevated amino acids and serves to supply sufficient pyruvate for increased Krebs cycle flux when glucose is limiting.
Journal of Biological Chemistry | 2009
Romana Stark; Francisco Pasquel; Adina Turcu; Rebecca L. Pongratz; Michael Roden; Gary W. Cline; Gerald I. Shulman; Richard G. Kibbey
Pancreatic β-cells couple the oxidation of glucose to the secretion of insulin. Apart from the canonical KATP-dependent glucose-stimulated insulin secretion (GSIS), there are important KATP-independent mechanisms involving both anaplerosis and mitochondrial GTP (mtGTP). How mtGTP that is trapped within the mitochondrial matrix regulates the cytosolic calcium increases that drive GSIS remains a mystery. Here we have investigated whether the mitochondrial isoform of phosphoenolpyruvate carboxykinase (PEPCK-M) is the GTPase linking hydrolysis of mtGTP made by succinyl-CoA synthetase (SCS-GTP) to an anaplerotic pathway producing phosphoenolpyruvate (PEP). Although cytosolic PEPCK (PEPCK-C) is absent, PEPCK-M message and protein were detected in INS-1 832/13 cells, rat islets, and mouse islets. PEPCK enzymatic activity is half that of primary hepatocytes and is localized exclusively to the mitochondria. Novel 13C-labeling strategies in INS-1 832/13 cells and islets measured substantial contribution of PEPCK-M to the synthesis of PEP. As high as 30% of PEP in INS-1 832/13 cells and 41% of PEP in rat islets came from PEPCK-M. The contribution of PEPCK-M to overall PEP synthesis more than tripled with glucose stimulation. Silencing the PEPCK-M gene completely inhibited GSIS underscoring its central role in mitochondrial metabolism-mediated insulin secretion. Given that mtGTP synthesized by SCS-GTP is an indicator of TCA flux that is crucial for GSIS, PEPCK-M is a strong candidate to link mtGTP synthesis with insulin release through anaplerotic PEP cycling.
Journal of Clinical Investigation | 2015
Mourad Ferdaoussi; Xiao-Qing Dai; Mette V. Jensen; Runsheng Wang; Brett S. Peterson; Chao Huang; Olga Ilkayeva; Nancy Smith; Nathanael Miller; Catherine Hajmrle; Aliya F. Spigelman; Robert C. Wright; Gregory Plummer; Kunimasa Suzuki; James P. Mackay; Martijn van de Bunt; Anna L. Gloyn; Terence E. Ryan; Lisa D. Norquay; M. Julia Brosnan; Jeff Trimmer; Timothy P. Rolph; Richard G. Kibbey; Jocelyn E. Manning Fox; William F. Colmers; Orian S. Shirihai; P. Darrell Neufer; Edward T.H. Yeh; Christopher B. Newgard; Patrick E. MacDonald
Insulin secretion from β cells of the pancreatic islets of Langerhans controls metabolic homeostasis and is impaired in individuals with type 2 diabetes (T2D). Increases in blood glucose trigger insulin release by closing ATP-sensitive K+ channels, depolarizing β cells, and opening voltage-dependent Ca2+ channels to elicit insulin exocytosis. However, one or more additional pathway(s) amplify the secretory response, likely at the distal exocytotic site. The mitochondrial export of isocitrate and engagement with cytosolic isocitrate dehydrogenase (ICDc) may be one key pathway, but the mechanism linking this to insulin secretion and its role in T2D have not been defined. Here, we show that the ICDc-dependent generation of NADPH and subsequent glutathione (GSH) reduction contribute to the amplification of insulin exocytosis via sentrin/SUMO-specific protease-1 (SENP1). In human T2D and an in vitro model of human islet dysfunction, the glucose-dependent amplification of exocytosis was impaired and could be rescued by introduction of signaling intermediates from this pathway. Moreover, islet-specific Senp1 deletion in mice caused impaired glucose tolerance by reducing the amplification of insulin exocytosis. Together, our results identify a pathway that links glucose metabolism to the amplification of insulin secretion and demonstrate that restoration of this axis rescues β cell function in T2D.